TB 402
Alternative Names: Anti factor VIII monoclonal antibody LE 2E9; Mab LE 2E9; TB-402; TGX Krix-1Latest Information Update: 11 Sep 2018
At a glance
- Originator University of Leuven
- Developer BioInvent International; ThromboGenics
- Class Anticoagulants; Antithrombotics; Monoclonal antibodies
- Mechanism of Action Factor VIII inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Venous thromboembolism
Most Recent Events
- 10 Sep 2018 Thrombogenics is now called Oxurion
- 05 Jun 2012 Discontinued - Phase-II for Venous thromboembolism in European Union (IV, Infusion)
- 05 Jun 2012 Discontinued - Phase-II for Venous thromboembolism in European Union (IV, Injection)